Effect of Combined Treatment with Levofloxacin and Metformin on Diabetes-the Diabetes Related Behavioral and Biochemical Alterations.

Objectives: The current experiment was conducted to investigate the combined effect of levofloxacin (LVX) and metformin treatment on blood glucose levels, malondialdehyde (MDA),nitrite levels, and anxiety in streptozotocin (STZ)+ nicotine adenine dinucleotide (NAD)-induced diabetic rats.

Materials And Methods: In this study, Wistar rats have been used. After receiving a single dose of STZ + NAD (45 mg/kg, + 50 mg/kg, ), the rats developed diabetes. Glucose levels in diabetic rats exceeded 200 mg/dL (verified on the third day). Saline was administered to non-diabetic rats (controls). Thediabetic rats were administered metformin (50 mg/kg, .), LVX (30 mg/kg, ), or metformin + LVX for 14 days. Blood samples were obtained after the 14 day of therapy, and the rats were given behavioral parameters to determine locomotor activity and anxiety level. Blood plasma samples were separately collected for the determination of nitrite and MDA levels.

Results: It was observed that the combined treatment of metformin and LVX significantly increased glucose levels in the blood of diabetic rats compared with diabetic control ( < 0.05) and diabetic rats treated with metformin alone ( < 0.001) at days 3 and 7. Further, combined treatment of metformin and LVX significantly reduced time spent at the center of the open field test ( < 0.001), significantly reduced time spent and entry made in the light chamber of the light-dark test ( < 0.001), significantly increased time spent in the open arm and reduced the time spent in the closed arm of the Elevated plus maze ( < 0.001) compared with alone metformin-treated diabetic rats. Further, combined treatment with metformin and LVX significantly increased the nitrite level, ( < 0.001) but reduced the MDA level in plasma compared with metformin alone-treated diabetic rats ( <0.001).

Conclusion: The present study suggests that combined treatments with levofloxacin and metformin may modulate glucose levels and anxiety-related activity.